CytoSorbents Corporation (CTSO)

[HadToHavit]

Yea.. nothing going on at Cytosorbents….
A large, single center, retrospective study was recently published in 336 patients who had undergone aortic surgery involving hypothermic circulatory arrest (HCA) entitled, “Haemadsorption improves intraoperative haemodynamics and metabolic changes during aortic surgery with hypothermic circulatory arrest“. In the study, 168 patients with CytoSorb hemoadsorption used intraoperatively during cardiopulmonary bypass were matched by propensity score to 168 patients receiving standard therapy without CytoSorb (control). The use of CytoSorb significantly reduced the requirement for artificial blood pressure support using vasopressors (p=0.043), with a more stable acid-base balance and lower lactate levels throughout the procedure. CytoSorb use also significantly decreased the need for transfusion of packed red blood cells (p=0.021) and fresh frozen plasma (p=0.001), but increased the use of prothrombin complex concentrate (p=0.004). A trend to improved 30-day mortality (CytoSorb: 4.8%; Control: 8.8%) was observed but not statistically significant. The authors concluded that the use of CytoSorb in the setting of acute aortic surgery with HCA significantly reduces the need for vasopressors, the amount of transfusion, and improves acid-based balance.